PDB21 Chart Audit and Budget Impact Analysis of Pasireotide Versus Second-Line Therapies in the Treatment of Cushing's Disease in Germany
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1664
https://www.valueinhealthjournal.com/article/S1098-3015(12)03377-3/fulltext
Title :
PDB21 Chart Audit and Budget Impact Analysis of Pasireotide Versus Second-Line Therapies in the Treatment of Cushing's Disease in Germany
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03377-3&doi=10.1016/j.jval.2012.08.1664
First page :
A497
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
1155